News | September 29, 2025
This predictive technology empowers people with diabetes to take preventive action before complications arise
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
Cagrilintide represents a novel approach to obesity management
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Subscribe To Our Newsletter & Stay Updated
